Revance Begins Injectable Trial

Revance Therapeutics, a biopharmaceutical company, has announced Phase 2 BELMONT trial. This randomized, double-blind, dose ranging, active, and placebo controlled, multicenter study will evaluate the safety and efficacy of RT002, a botulinum toxin type A injectable intended to treat glabellar lines. The RT002 has the potential to address additional therapeutic indications where more targeted delivery is required or a longer duration is desired, for example movement disorders, urology, and ophthalmology. There are 250 participants expected to enroll at up to 10 sites in Canada. “The opportunity for a longer-lasting, more targeted neurotoxin is tremendous as it offers the potential for improved patient satisfaction and safety with longer-lasting results,” says Dan Browne, cofounder, president, and CEO of Revance Therapeutics. “Based on the current progress of our program, we expect to report top-line date from this Phase 2 study in late 2015.”

Suggested Articles

INhance Post-Injection Serum with TriHex Technology is designed to alleviate bruising caused by cosmetic procedures.

Medical pedicures at Medi Pedi NYC focus specifically on feet and nail health.

Plastic surgery practices have started reopening, allowing clients to receive elective treatments of the face and neck.